Table 2.
Broad spectrum activity of BBI608 against stemness-high cancer cells
| Cell line | IC50 (uM) |
| U87-MG (glioblastoma; astrocytoma) | 0.729 |
| U118 (glioblastoma; astrocytoma) | 0.930 |
| COLO205 (colorectal adenocarcinoma) | 0.870 |
| DLD1 (colorectal adenocarcinoma) | 0.996 |
| SW480 (colorectal adenocarcinoma) | 1.231 |
| HCT116 (colorectal carcinoma) | 1.249 |
| FaDu (head and neck squamous cell carcinoma) | 0.616 |
| ACHN (renal cell adenocarcinoma) | 1.190 |
| SNU-475 (hepatocellular carcinoma) | 0.479 |
| Huh7 (hepatocellular carcinoma) | 0.926 |
| HepG2 (hepatocellular carcinoma) | 1.057 |
| H1975 (non-small cell lung cancer; adenocarcinoma) | 0.549 |
| A549 (non-small cell lung cancer; adenocarcinoma) | 1.130 |
| H460 (large cell lung cancer; carcinoma) | 1.185 |
| CAOV-3 (ovarian adenocarcinoma) | 0.291 |
| SW-626 (ovarian adenocarcinoma) | 0.432 |
| PaCa2 (pancreatic carcinoma) | 0.624 |
Beginning with single-cell suspensions from dissociated sphere cultures, cancer stem cells were grown for 3 d to allow for sphere formation and then treated with BBI608, and viability was assessed after 24 h. Data (IC50, uM) represent averages of three separate experiments.